The U.S. deep brain stimulation in Parkinson’s disease market was estimated at USD 453.87 million in 2021 and it is expected to surpass around USD 849.71 million by 2030, poised to grow at a CAGR of 7.22% from 2022 to 2030.
The U.S. deep brain stimulation in Parkinson’s disease market was estimated at USD 453.87 million in 2021 and it is expected to surpass around USD 849.71 million by 2030, poised to grow at a CAGR of 7.22% from 2022 to 2030.
Report Highlights
- The dual-channel led the market and accounted for more than 55.0% share in 2021.
- The single-channel segment is anticipated to witness the fastest growth over the forecast period.
- By product, the U.S. deep brain stimulation in Parkinson’s disease market was valued at USD 453.8 billion in 2021 and expected to witness growth at a CAGR of 7.54% from 2022 to 2030.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39360
The rising prevalence of neurological conditions, such as Parkinson’s Disease (PD), increasing awareness, positive research outcomes, and growing investments in the development of transcranial stimulators are among the major factors driving the overall U.S DBS devices market.
DBS devices have been observed to be greatly effective in controlling the tremors associated with PD. They provide electrical stimulation to the basal ganglia, which results in suppressed neuronal activity that is generally spontaneous in patients suffering from PD. Low dopamine levels and other genetic factors are the main causes of PD. According to the Parkinson’s Foundation, about 1 million people are expected to be living with PD in the U.S. by 2020. Men are more susceptible to this disease than women.
Increasing investments for conducting R&D on PD have helped in raising awareness and boosting the development of new and innovative products and therapies for the treatment of this disease. For instance, the National Parkinson Foundation (NPF) provides funds to researchers and scientists with an aim to make advancements in this field. Extensive research activities for the inclusion and approval of deep brain stimulators in new application areas, such as full-body MRI scans and depression, are anticipated to boost the market growth over the forecast period. The DBS procedure price in the U.S. is around USD 96,000. It is expensive as compared with the cost of DBS procedures in countries such as the U.K. and Japan.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 453.87 million |
| Revenue Forecast by 2030 | USD 849.71 million |
| Growth rate from 2022 to 2030 | CAGR of 7.22% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Product |
| Companies Covered | Boston Scientific Corporation; Abbott; Medtronic; Functional Neuromodulation; Nuvectra Corporation; Aleva Neurotherapeutics SA |
Product Insights
The dual-channel led the market and accounted for more than 55.0% share in 2021. High-frequency DBS has become a widely utilized procedure for the management of severe momentum disorders when the symptoms can no longer be improved by medical treatment. The procedure is safe, bilateral, and reversible. It can be performed by bilateral implantation of leads into the target areas. Growing adoption of double-channel DBS for the treatment of numerous neurological disorders, such as Parkinson’s disease, dystonia, Alzheimer’s disease, and epilepsy, is a key factor fueling segment growth.
Moreover, technological advancements and new product launches are further impelling segment growth. For instance, in January 2020, Abbott’s Infinity DBS system secured FDA approval for the treatment of Parkinson’s disease from the U.S. FDA. This system will allow targeting of a specific area of the brain called internal Globus Pallidus (GPi), which is associated with Parkinson’s disease symptoms. In addition, Vercise, Vercise PC, & Vercise Gevia DBS systems by Boston Scientific; Activa PC & Activa RC by Medtronic; and Infinity by Abbott are some of the key offerings under the segment.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39360
The single-channel segment is anticipated to witness the fastest growth over the forecast period. A Deep Brain Stimulator (DBS) device is also known as brain pacemaker and has been clinically used over the past 25 years for the treatment of Parkinson’s disease. The single-channel DBS systems are used for patients who have only one lead implanted. Healthcare professionals consider that a single channel offers the neurologist more programming options and provides better motor results, which led to the increased preference for single-channel DBS.
A rise in the geriatric population, which is more prone to developing Parkinson’s disease, and growing awareness about neurological movement disorders among patients are anticipated to impel the growth of the segment. For instance, as per the World Ageing 2019 report, it is estimated that globally, there were about 703 million people aged 65 years in 2019. Furthermore, in March 2018, the Brain & Spine Foundation (BSF) and Neurological Alliance launched “Brain Awareness Week,” a global campaign to increase awareness about progress in diagnosis, treatment, and prevention of neurological conditions. One of the key products offered under this segment is Activa SC, which is a single-channel DBS offered by Medtronic. Activa SC controls one-DBS electrode, which has been approved for the treatment of Parkinson’s disease.
Key Players
- Boston Scientific Corporation
- Abbott
- Medtronic
- Functional Neuromodulation
- Nuvectra Corporation
- Aleva Neurotherapeutics SA
Market Segmentation
Product Outlook
-
- Single-channel
- Dual-channel
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39360
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333